Sasha Arbid remembers long nights combing through medical journals — not for an assignment, but for answers.
As a pre-med undergraduate student, he developed a severe autoimmune condition triggered by COVID-19. Doctors told him there was no cure. Arbid refused to accept that.
While continuing his studies and working at University Health Network, he began reviewing clinical literature and experimental treatments. His search led to an Eli Lilly and Company-developed drug. After years of persistence, including convincing a physician to try the drug for his condition, Arbid began treatment. Sixteen months later, he had fully recovered.
The experience changed everything. It not only eventually led him to contribute to the Canadian launch of the drug that cured him, but also to the Master of Science in Biotechnology at Northeastern University in Toronto.
Read more at Northeastern Global News
Courtesy photo
